General Hospital Psychiatry
Volume 32, Issue 4 , Pages e9-e10 , July 2010

Ecchymoses as an adverse effect of fluvoxamine treatment in an adolescent girl

References 

  1. Weinrieb RM, Auriacombe M, Lynch KG, Lewis JD. Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Saf. 2005;4:337–344
  2. Leung M, Shore R. Fluvoxamine-associated bleeding. Can J Psychiatry. 1996;41(9):604–605
  3. Ottervanger JP, van den Bemt PM, de Koning GH, Stricker BH. Risk of hemorrhage with the use of fluoxetine (Prozac) or fluvoxamine (Fevarin). Ned Tijdschr Geneeskd. 1993;137:259–261
  4. Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ. Fluoxetine and bleeding in obsessive-compulsive disorder [letter]. Am J Psychiatry. 1991;148:949
  5. Calhoun JW, Calhoun DD. Prolonged bleeding time in a patient treated with sertraline. [letter] Am J Psychiatry. 1996;153:443
  6. Lake MB, Birmaher B, Wassick S, Mathos K, Yelovich AK. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol. 2000;10:35–38
  7. Holzer L, Halfon O. Sertraline and gastrointestinal bleeding in an adolescent girl. J Child Adolesc Psychopharmacol. 2006;16:1–2
  8. McCloskey DJ, Postolache TT, Vittone BJ, et al. Selective serotonin reuptake inhibitors (SSRIs): measurement of effect on platelet function. Transl Res. 2008;151:168–172

PII: S0163-8343(10)00006-X

doi: 10.1016/j.genhosppsych.2010.01.005

General Hospital Psychiatry
Volume 32, Issue 4 , Pages e9-e10 , July 2010

Article Tools